We are live on
!
Find out more
GT
Glenmede Trust Portfolio holdings
AUM
$20.4B
This Fund
S&P 500
This Quarter
Est. Return
+8.99%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$21.9B
AUM Growth
+$21.9B
(+100,205%)
Cap. Flow
-$417M
Cap. Flow
% of AUM
-1.9%
Top 10 Holdings %
Top 10 Hldgs %
13.08%
Holding
3,337
New
135
Increased
1,103
Reduced
1,007
Closed
163
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$89.3M |
| 2 |
Keysight
KEYS
|
+$86M |
| 3 |
Nike
NKE
|
+$78.3M |
| 4 |
Amphenol
APH
|
+$76.5M |
| 5 |
Comcast
CMCSA
|
+$72.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Celanese
CE
|
+$108M |
| 2 |
Monster Beverage
MNST
|
+$97.8M |
| 3 |
Starbucks
SBUX
|
+$79.7M |
| 4 |
Texas Instruments
TXN
|
+$67.3M |
| 5 |
Centene
CNC
|
+$64.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.83% |
| 2 | Financials | 13.42% |
| 3 | Healthcare | 13.25% |
| 4 | Industrials | 9.77% |
| 5 | Consumer Discretionary | 7.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
701
Omega Healthcare
OHI
$15.3B
| $772K | ﹤0.01% |
18,260
| – | – |
|
702
BCE
BCE
$19.8B
| $767K | ﹤0.01% |
16,568
+4,785
| +41% | +$229K |
|
703
iShares Core Dividend Growth ETF
DGRO
$42.8B
| $766K | ﹤0.01% |
18,221
-1,112
| -6% | -$45K |
|
704
Alliant Energy
LNT
$19.1B
| $760K | ﹤0.01% |
13,890
+783
| +6% | +$41.6K |
|
705
CNA Financial
CNA
$14.7B
| $759K | ﹤0.01% |
16,940
-33,700
| -67% | -$1.52M |
|
706
iShares MSCI Emerging Markets Min Vol Factor ETF
EEMV
$3.47B
| $750K | ﹤0.01% |
12,797
-900
| -7% | -$52.2K |
|
707
Shake Shack
SHAK
$2.48B
| $750K | ﹤0.01% |
12,608
+107
| +0.9% | +$7.69K |
|
708
Western Digital
WDC
$172B
| $749K | ﹤0.01% |
15,625
+12,889
| +471% | +$538K |
|
709
Brookfield Infrastructure Partners
BIP
$18.6B
| $748K | ﹤0.01% |
25,192
+6,586
| +35% | +$197K |
|
710
WSFS Financial
WSFS
$4.14B
| $742K | ﹤0.01% |
16,884
+11,766
| +230% | +$514K |
|
711
HubSpot
HUBS
$11.4B
| $741K | ﹤0.01% |
4,680
-310
| -6% | -$47.5K |
|
712
iShares US Technology ETF
IYW
$23.3B
| $729K | ﹤0.01% |
12,552
| – | – |
|
713
Edison International
EIX
$30.3B
| $724K | ﹤0.01% |
9,619
-200
| -2% | -$14.2K |
|
714
Vodafone
VOD
$36.4B
| $718K | ﹤0.01% |
37,192
-2,858
| -7% | -$56.9K |
|
715
Columbia Banking Systems
COLB
$8.74B
| $717K | ﹤0.01% |
17,628
+2,444
| +16% | +$95.2K |
|
|
TRCB
716
DELISTED
Two River Bancorp
TRCB
| $705K | ﹤0.01% |
31,506
-2,250
| -7% | -$47.7K |
|
717
Bank of Hawaii
BOH
$3.17B
| $699K | ﹤0.01% |
7,364
-10
| -0.1% | -$889 |
|
718
Casey's General Stores
CASY
$31.6B
| $698K | ﹤0.01% |
4,395
-191
| -4% | -$31.6K |
|
719
Nomad Foods
NOMD
$1.67B
| $698K | ﹤0.01% |
31,239
+1,444
| +5% | +$29.4K |
|
720
Chesapeake Utilities
CPK
$3.26B
| $694K | ﹤0.01% |
7,251
-625
| -8% | -$58.1K |
|
721
Semtech
SMTC
$11.3B
| $692K | ﹤0.01% |
13,100
-1,409
| -10% | -$70.6K |
|
|
ATH
722
DELISTED
Athene Holding Ltd. Class A Common Shares
ATH
| $688K | ﹤0.01% |
14,637
-55
| -0.4% | -$2.39K |
|
723
Triumph Financial Inc
TFIN
$1.8B
| $680K | ﹤0.01% |
17,895
+2,855
| +19% | +$98.6K |
|
724
Arrowhead Research
ARWR
$12B
| $678K | ﹤0.01% |
10,697
+54
| +0.5% | +$2.68K |
|
725
Leidos
LDOS
$14.5B
| $675K | ﹤0.01% |
6,909
+6,186
| +856% | +$545K |
|
Similar funds
SLAM
EWA
MIC
P
OSAM
CB
EIM
Glenmede Trust's Q4 2019 Portfolio in Review
As of Q4 2019, Glenmede Trust held 3,337 positions worth $21.9B, up 100,205% from $21.9M the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Glenmede Trust's Q4 2019 filing shows 135 new, 1,103 increased, 1,007 reduced and 163 closed positions. Its largest new stake was Callon Petroleum Company: 285,674 shares worth $13.8M. The largest sale was Celanese, an estimated $108M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Financials and Healthcare.
- Glenmede Trust's largest Q4 2019 buy was Callon Petroleum Company: 285,674 shares worth $13.8M.
- Glenmede Trust added most to Bristol-Myers Squibb in Q4 2019, an estimated $89.3M increase.
- Glenmede Trust's biggest Q4 2019 reduction was Celanese, cutting an estimated $108M.
- Glenmede Trust fully exited Celgene Corp in Q4 2019, selling an estimated $122K.
- Glenmede Trust's ten largest holdings make up 13% of its $21.9B portfolio in Q4 2019.
- Glenmede Trust opened 135 new positions and closed 163 in Q4 2019.
- Glenmede Trust's portfolio value rose 100,205% quarter-over-quarter to $21.9B.
Based on Glenmede Trust's 13F filing for Q4 2019, filed 12 Feb 2020.